论文部分内容阅读
我们于1991年—1994年经用卡兰治疗缺血性脑血管病(ICVD)128例,通过观察红细胞变形能力(RCD)改变,探讨ICVD的RCD降低发生机理及卡兰治疗ICVD的作用机制,现报道如下.1 资料与方法1.1 资料 本组128例均经CT证实.其中脑血栓120例、脑栓塞8例;男72例、女56例;年龄34～71岁、平均56.7岁.对照组为本院健康职工,男57名、女43名,年龄36～72岁,平均54.3岁.1.2 方法 卡兰片每次5mg,日服3次,4～6周为一疗程.1.3 RCD测定 采集空腹抗凝静脉血2ml,测定RCD并算出细胞变形指数(IF).仪器为滤过细胞测定仪(江苏锡山市光学仪器厂生产,型号为XBH—30)及核孔滤膜(中科院高能物
In our study, 128 patients with ischemic cerebrovascular disease (ICVD) were treated with Kalan from 1991 to 1994. The mechanism of RCD reduction in ICVD and the mechanism of action of Kalan on ICVD were investigated by observing the changes of erythrocyte deformability (RCD) Are reported as follows.1 Materials and Methods 1.1 Data 128 cases of this group have been confirmed by CT, of which 120 cases of cerebral thrombosis, cerebral embolism in 8 cases; 72 males and 56 females, aged 34 to 71 years, mean 56.7 years .Control group For the hospital health workers, 57 males and 43 females, aged 36 to 72 years, an average of 54.3 years.1.2 MethodsCarrenal tablets each 5mg, 3 times a day, 4 to 6 weeks for a course of treatment .1.3 RCD measurement acquisition Fasting anticoagulant venous blood 2ml, determination of RCD and calculate the cell deformation index (IF) .Filter for the cytometer (Jiangsu Xishan Optical Instrument Factory production, model XBH-30) and nuclear pore filter (Chinese Academy of Sciences